guest ::
| Home > Publications database > Aggressive primary cutaneous B-cell lymphomas show increased Angiopoietin-2-induced angiogenesis. > print |
| Home > Publications database > Aggressive primary cutaneous B-cell lymphomas show increased Angiopoietin-2-induced angiogenesis. > print |
| 001 | 127608 | ||
| 005 | 20240228140939.0 | ||
| 024 | 7 | _ | |a 10.1111/exd.12688 |2 doi |
| 024 | 7 | _ | |a pmid:25776770 |2 pmid |
| 024 | 7 | _ | |a 0906-6705 |2 ISSN |
| 024 | 7 | _ | |a 1600-0625 |2 ISSN |
| 024 | 7 | _ | |a altmetric:7140028 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-03631 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Teichert, Martin |0 P:(DE-HGF)0 |b 0 |e First author |
| 245 | _ | _ | |a Aggressive primary cutaneous B-cell lymphomas show increased Angiopoietin-2-induced angiogenesis. |
| 260 | _ | _ | |a Oxford |c 2015 |b Wiley-Blackwell |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1521117015_29680 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Primary cutaneous large B-cell lymphomas, leg type (PCLBCL/LT) are primary cutaneous B-cell lymphoma (PCBCL) with an intermediate prognosis. Therefore, antracycline-based polychemotherapy combined with rituximab has been recommended as first-line treatment. Yet, despite this regimen, the 5-year survival rate remains 50-66% only. Angiogenesis, the formation of a vascular network, is essential for the pathogenesis of nodal lymphomas. So far, no study has analysed angiogenesis and its key factors in PCLBCL/LT. The present study was aimed at characterizing angiogenesis in PCLBCL/LT to identify the angiogenic molecules as potential therapeutic targets. The intra-tumoral microvessel density (MVD) was assessed by immunohistochemical studies of CD20 and CD31. The MVD was higher in PCLBCL/LT compared with indolent PCBCL. Analyses of open-source microarray data showed correlation between the angiogenic molecule angiopoietin-2 (Ang-2) and pan-endothelial cell markers. ELISA studies determined a shift between Ang-2 and Ang-1 towards Ang-2 in the peripheral blood of PCLBCL/LT patients. Immunofluorescence costainings against the Ang receptor Tie2/angiogenic integrins/CD34 revealed that the vasculature in both aggressive and indolent PCBCL tumors harbours an endothelial cell subpopulation with reduced expression of Tie2. In contrast, the alternative Ang-2 binding partners, angiogenic integrins, are strongly expressed in PCBCL. In line with these findings, downstream targets of Ang-2-integrin signalling, that is phosphorylation of focal adhesion kinase at Tyr397, and sprouting angiogenesis are enhanced in PCLBCL/LT. Our data present Ang-2 as a promising therapeutic target and anti-angiogenic therapy as a new line in treatment of PCLBCL/LT as a hitherto intractable disease. |
| 536 | _ | _ | |a 311 - Signalling pathways, cell and tumor biology (POF3-311) |0 G:(DE-HGF)POF3-311 |c POF3-311 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a ANGPT2 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Angiopoietin-2 |2 NLM Chemicals |
| 650 | _ | 7 | |a Integrins |2 NLM Chemicals |
| 650 | _ | 7 | |a Focal Adhesion Protein-Tyrosine Kinases |0 EC 2.7.10.2 |2 NLM Chemicals |
| 700 | 1 | _ | |a Stumpf, Christine |b 1 |
| 700 | 1 | _ | |a Booken, Nina |b 2 |
| 700 | 1 | _ | |a Wobser, Marion |b 3 |
| 700 | 1 | _ | |a Nashan, Dorothee |b 4 |
| 700 | 1 | _ | |a Hallermann, Christian |b 5 |
| 700 | 1 | _ | |a Mogler, Carolin |0 P:(DE-He78)18e5b355e4a312d2065b1ae2a9d47654 |b 6 |u dkfz |
| 700 | 1 | _ | |a Müller, Cornelia S L |b 7 |
| 700 | 1 | _ | |a Becker, Jürgen |0 P:(DE-He78)7bf2f090fe39a6cd6f0bccf5ea2d4fb3 |b 8 |u dkfz |
| 700 | 1 | _ | |a Moritz, Rose K C |b 9 |
| 700 | 1 | _ | |a Andrulis, Mindaugas |b 10 |
| 700 | 1 | _ | |a Nicolay, Jan P |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Goerdt, Sergij |b 12 |
| 700 | 1 | _ | |a Thomas, Markus |b 13 |
| 700 | 1 | _ | |a Klemke, Claus-Detlev |b 14 |
| 700 | 1 | _ | |a Augustin, Hellmut |0 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b |b 15 |u dkfz |
| 700 | 1 | _ | |a Felcht, Moritz |0 P:(DE-He78)28b708d8e88fbb959e31ff6770aaa6c7 |b 16 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1111/exd.12688 |g Vol. 24, no. 6, p. 424 - 429 |0 PERI:(DE-600)2026228-0 |n 6 |p 424 - 429 |t Experimental dermatology |v 24 |y 2015 |x 0906-6705 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:127608 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)18e5b355e4a312d2065b1ae2a9d47654 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)7bf2f090fe39a6cd6f0bccf5ea2d4fb3 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-He78)28b708d8e88fbb959e31ff6770aaa6c7 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-311 |2 G:(DE-HGF)POF3-300 |v Signalling pathways, cell and tumor biology |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2015 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EXP DERMATOL : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)A190-20160331 |k A190 |l Vaskuläre Onkologie und Metastasierung |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)L401-20160331 |k L401 |l DKTK Essen |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)L101-20160331 |k L101 |l DKTK Heidelberg |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A190-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L401-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L101-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|